FDA granted Orphan Drug Designation to Toca 511 & Toca FC, an investigational immunotherapy treatment for glioblastoma developed by Tocagen.
The European Commission granted a marketing authorization for Unituxin (dinutuximab) for the treatment of high-risk neuroblastoma in patients aged 12 months to 17 years, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and autologous stem cell transplantation.
THE CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS awarded seven grants through its academic research program. The grants, totaling $23 million, support the recruitment of seven cancer scientists to academic institutions in Texas, including two distinguished senior researchers.
ECOG-ACRIN opened the NCI-MATCH precision medicine trial, the largest, most scientifically rigorous precision medicine trial in cancer to date.
NORTHWESTERN MEDICINE and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University officially named the Lynn Sage Cancer Research Foundation Breast Cancer OncoSET program.
A federal judge ruled that Amgen Inc. cannot force me to answer questions related to a 2007 story that sparked a class action suit by investors and triggered a change in FDA regulations of erythropoiesis-stimulating agents.
KEITH PERRY was named as chief information officer of St. Jude Children's Research Hospital.
After years of turmoil and plunging morale at MD Anderson Cancer Center, the UT System took what observers describe as an unprecedented step—forming a Shared Governance Committee.
DONALD SHELDON was appointed to the new role of regional president of community hospitals for University Hospitals.
RACHEL HUMPHREY was named chief medical officer of CytomX. Humphrey previously served as a member of the company's board of directors.